Professor Jack Cuzick

CBE, PhD, FRS, FMedSci, FRCP (hon)
John Snow Professor of Epidemiology
Research Theme Lead
Research Focus

I am John Snow Professor of Epidemiology at Queen Mary University of London. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.

Key Publications

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658

A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881

Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741

Major Funding
  • 2018-2023- CRUK, Catalyst
  • 2017-2020- Barts Charity, Preventative Neurology
  • 2014-2019- CRUK, Cancer Prevention
  • 2007-2019- CRUK, IBIS II
Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Major Funding
  • 2018-2023- CRUK, Catalyst
  • 2017-2020- Barts Charity, Preventative Neurology
  • 2014-2019- CRUK, Cancer Prevention
  • 2007-2019- CRUK, IBIS II
Recent Publications

Obesity at age 20 and weight gain during adulthood increase risk of total and premature all-cause mortality: findings from women attending breast screening in Manchester Pegington M, Harvie M, Harkness EF et al. BMC Women's Health (2023) 23(7)

Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States. Cuzick J, Adcock R, Kinney W et al. Int J Cancer (2023) (2)
https://www.ncbi.nlm.nih.gov/pubmed/36946690

Abstract PD14-01: PD14-01 A model to assess the utility of risk-based screening algorithms Atakpa EC, Cuzick J, Duffy SW et al. Cancer Research (2023) 83(10) pd14-01-pd14-01

The importance of long-term follow up of participants in clinical trials Cuzick J British Journal of Cancer (2023) 128(7) 432-438

A case–control study to evaluate the impact of the breast screening programme on breast cancer incidence in England Blyuss O, Dibden A, Massat NJ et al. Cancer Medicine (2023) 12(7) 1878-1887

Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets Berney DM, Finnegan K, Chu K et al. Histopathology (2023) (7)

Interpreting the results of noninferiority trials—a review Cuzick J, Sasieni P British Journal of Cancer (2022) 127(7) 1755-1759

39. Associations between somatically altered genes and recurrence outcomes in estrogen receptor positive breast cancer Anurag M, Chu K, Li B et al. Cancer Genetics (2022) 268(10) 13

Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing. Dinneen E, Shaw GL, Kealy R et al. BJUI Compass (2022) 3(2) 458-465
https://www.ncbi.nlm.nih.gov/pubmed/36267207

DNA methylation testing with S5 for triage of high-risk HPV positive women Adcock R, Nedjai B, Lorincz AT et al. International Journal of Cancer (2022) 151(7) 993-1004

For additional publications, please click here
Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.